Calyxt Inc (NASDAQ:CLXT) Director Michel Arbadji sold 6,500 shares of the company’s stock in a transaction dated Wednesday, June 20th. The stock was sold at an average price of $22.00, for a total transaction of $143,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
CLXT traded down $0.24 during midday trading on Friday, reaching $20.38. The company’s stock had a trading volume of 154,248 shares, compared to its average volume of 124,140. The company has a debt-to-equity ratio of 0.27, a quick ratio of 17.79 and a current ratio of 17.79. Calyxt Inc has a 1 year low of $9.26 and a 1 year high of $31.89.
Calyxt (NASDAQ:CLXT) last announced its quarterly earnings data on Monday, May 7th. The company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.13. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.20 million. Calyxt had a negative net margin of 5,930.60% and a negative return on equity of 60.81%. equities analysts expect that Calyxt Inc will post -1.14 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in CLXT. Wells Fargo & Company MN grew its holdings in Calyxt by 1,421.9% in the fourth quarter. Wells Fargo & Company MN now owns 30,788 shares of the company’s stock worth $678,000 after purchasing an additional 28,765 shares during the period. BlackRock Inc. grew its holdings in shares of Calyxt by 102.8% during the fourth quarter. BlackRock Inc. now owns 740,010 shares of the company’s stock valued at $16,302,000 after buying an additional 375,137 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Calyxt by 151.3% during the fourth quarter. Deutsche Bank AG now owns 18,378 shares of the company’s stock valued at $404,000 after buying an additional 11,064 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Calyxt during the fourth quarter valued at approximately $330,000. Institutional investors and hedge funds own 21.78% of the company’s stock.
A number of equities research analysts have weighed in on CLXT shares. Jefferies Financial Group restated a “buy” rating and issued a $27.00 price objective on shares of Calyxt in a report on Thursday, March 1st. ValuEngine upgraded shares of Calyxt from a “sell” rating to a “hold” rating in a report on Wednesday, March 14th. Finally, Zacks Investment Research upgraded shares of Calyxt from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a report on Monday, May 28th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $27.38.
Calyxt Company Profile
Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for plants in the United States. It engages in the development of high oleic soybeans, high fiber wheat, herbicide tolerant wheat, powdery mildew resistant wheat, enhanced oil composition and herbicide tolerant canola, enhanced quality and herbicide tolerant alfalfa, late blight resistant potatoes, and cold storable/reduced browning potatoes, as well as enhanced protein composition, drought tolerant, herbicide tolerant, and enhanced yield soybeans.
Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.